Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib plasma concentration study in gastrointestinal stromal tumor patients intolerant to 400 mg/day
ChiCTR-OPN-15006162Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Plasma concentration of imatinib and Clinical efficacy (recurrence/metastasis). Planned start Jun 2015; status: not yet recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR-OPN-15006162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-15006162.